Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 2/20 | 0.43 |
| ▸ | TGFBR1 | P36897 | 4/20 | 0.39 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.39 |
| ▸ | CDK8 | P49336 | 7/20 | 0.39 |
| ▸ | CCNC | P24863 | 4/20 | 0.39 |
| ▸ | CDK19 | Q9BWU1 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.35 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.35 |
| ▸ | XIAP | P98170 | 1/20 | 0.35 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3747756 | 0.83 | ALDH1A1 (0.39) | TGFBR1SLC22A12SMN1; SMN2NPC1RAB9A | |
| SCHEMBL31461243 | 0.83 | ALDH1A1 (0.39) | TGFBR1SLC22A12SMN1; SMN2NPC1RAB9A | |
| SCHEMBL24322279 | 0.83 | CDK8 (0.39) | GRM5TGFBR1SLC22A12CDK8CCNC | |
| SCHEMBL5235225 | 0.82 | CYP1A2 (0.49) | GRM5TGFBR1SMN1; SMN2RAB9AALDH1A1 | |
| SCHEMBL29959459 | 0.82 | CYP1A2 (0.49) | GRM5TGFBR1SMN1; SMN2RAB9AALDH1A1 | |
| SCHEMBL23851296 | 0.81 | MTNR1A (0.52) | TGFBR1MAPK1ALDH1A1LMNA | |
| SCHEMBL31461239 | 0.81 | MTNR1A (0.52) | TGFBR1MAPK1ALDH1A1LMNA | |
| SCHEMBL4873486 | 0.80 | SMN1; SMN2 (0.47) | TGFBR1SMN1; SMN2NPC1RAB9APKM | |
| SCHEMBL12922149 | 0.80 | P2RX7 (0.36) | GRM5TGFBR1SLC22A12SMN1; SMN2NPC1 | |
| SCHEMBL5239692 | 0.80 | TGFBR1 (0.41) | TGFBR1SLC22A12CDK8CCNCMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108779115-B | Five-membered heteroaromatic ring bridged ring derivative, preparation method thereof and application thereof in medicine | 江苏恒瑞医药股份有限公司 | 2021-02-26 | — | — | CN | disclosed |
| US-10906905-B2 | Five-membered heteroaryl ring bridged ring derivative, preparation method therefor and medical use thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2021-02-02 | — | — | US | disclosed |
| US-20200055852-A1 | FIVE-MEMBERED HETEROARYL RING BRIDGED RING DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2020-02-20 | — | — | US | disclosed |
| EP-3527570-A1 | FIVE-MEMBERED HETEROARYL RING BRIDGED RING DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2019-08-21 | — | — | EP | disclosed |
| WO-2018068759-A1 | FIVE-MEMBERED HETEROARYL RING BRIDGED RING DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 江苏恒瑞医药股份有限公司 | 2018-04-19 | — | — | WO | disclosed |
| EP-1910370-B1 | A PYRIDIN QUINOLIN SUBSTITUTED PYRROLO [1,2-B] PYRAZOLE MONOHYDRATE AS TGF-BETA INHIBITOR | LILLY CO ELI (US) | 2015-04-22 | — | — | EP | disclosed |
| EP-1910370-B1 | A PYRIDIN QUINOLIN SUBSTITUTED PYRROLO [1,2-B] PYRAZOLE MONOHYDRATE AS TGF-BETA INHIBITOR | LILLY CO ELI (US) | 2015-04-22 | — | — | EP | disclosed |
| US-7872020-B2 | TGF-β inhibitors | ELI LILLY AND COMPANY (US) | 2011-01-18 | — | — | US | disclosed |
| US-7872020-B2 | TGF-β inhibitors | ELI LILLY AND COMPANY (US) | 2011-01-18 | — | — | US | disclosed |
| US-20100120854-A1 | TGF-BETA INHIBITORS | ELI LILLY AND COMPANY (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100120854-A1 | TGF-BETA INHIBITORS | ELI LILLY AND COMPANY (US) | 2010-05-13 | — | — | US | disclosed |
| EP-1910370-A1 | A PYRIDIN QUINOLIN SUBSTITUTED PYRROLO [1,2-B] PYRAZOLE MONOHYDRATE AS TGF-BETA INHIBITOR | ELI LILLY AND COMPANY (US) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007018818-A1 | A PYRIDIN QUINOLIN SUBSTITUTED PYRROLO [1,2-B] PYRAZOLE MONOHYDRATE AS TGF-BETA INHIBITOR | ELI LILLY AND COMPANY (US) | 2007-02-15 | — | — | WO | disclosed |
| WO-2007018818-A1 | A PYRIDIN QUINOLIN SUBSTITUTED PYRROLO [1,2-B] PYRAZOLE MONOHYDRATE AS TGF-BETA INHIBITOR | ELI LILLY AND COMPANY (US) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10906905-B2 | Five-membered heteroaryl ring bridged ring derivative, preparation method therefor and medical use thereof | TGFBR1, TGFB2, TGFB1 | GRM5 1869/4885TGFBR1 1/4885SLC22A12 1880/4885 |
| US-20200055852-A1 | FIVE-MEMBERED HETEROARYL RING BRIDGED RING DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | TGFBR1, TGFB2, TGFB1 | GRM5 1869/4885TGFBR1 1/4885SLC22A12 1880/4885 |
| US-20100120854-A1 | TGF-BETA INHIBITORS | TGFBR1, TGFBR2, SMAD3 | GRM5 2490/4885TGFBR1 1/4885SLC22A12 3800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.